Lev Gertsik

625 total citations
24 papers, 479 citations indexed

About

Lev Gertsik is a scholar working on Psychiatry and Mental health, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Lev Gertsik has authored 24 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 9 papers in Molecular Biology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Lev Gertsik's work include Bipolar Disorder and Treatment (7 papers), Receptor Mechanisms and Signaling (6 papers) and Treatment of Major Depression (5 papers). Lev Gertsik is often cited by papers focused on Bipolar Disorder and Treatment (7 papers), Receptor Mechanisms and Signaling (6 papers) and Treatment of Major Depression (5 papers). Lev Gertsik collaborates with scholars based in United States, United Kingdom and Switzerland. Lev Gertsik's co-authors include Russell E. Poland, Mark Hyman Rapaport, Catherine Bresee, Larry Ereshefsky, Mark A. Smith, James Doherty, A.J. Cross, Stephen R. Zukin, Robert E. Litman and Uma Rao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neuropsychopharmacology and Molecular Psychiatry.

In The Last Decade

Lev Gertsik

24 papers receiving 464 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lev Gertsik United States 12 151 147 131 130 86 24 479
Nuria García‐Marchena Spain 15 182 1.2× 146 1.0× 95 0.7× 165 1.3× 54 0.6× 35 558
Janice Shaw United States 12 293 1.9× 131 0.9× 216 1.6× 94 0.7× 93 1.1× 15 739
Haruhiko Sugino Japan 8 195 1.3× 216 1.5× 109 0.8× 165 1.3× 64 0.7× 8 710
Lucija Tudor Croatia 16 101 0.7× 77 0.5× 186 1.4× 193 1.5× 53 0.6× 43 669
Marie Naughton Ireland 8 172 1.1× 132 0.9× 105 0.8× 148 1.1× 73 0.8× 12 535
Luke A. Jelen United Kingdom 12 253 1.7× 252 1.7× 66 0.5× 203 1.6× 92 1.1× 23 691
Hans‐Willi Clement Germany 13 201 1.3× 70 0.5× 166 1.3× 92 0.7× 62 0.7× 31 671
Ani Gasparyan Spain 14 251 1.7× 462 3.1× 94 0.7× 107 0.8× 107 1.2× 31 792
Martha López-Canul Canada 11 330 2.2× 282 1.9× 88 0.7× 104 0.8× 150 1.7× 19 783
David Nutt United Kingdom 7 173 1.1× 184 1.3× 114 0.9× 80 0.6× 45 0.5× 10 541

Countries citing papers authored by Lev Gertsik

Since Specialization
Citations

This map shows the geographic impact of Lev Gertsik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lev Gertsik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lev Gertsik more than expected).

Fields of papers citing papers by Lev Gertsik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lev Gertsik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lev Gertsik. The network helps show where Lev Gertsik may publish in the future.

Co-authorship network of co-authors of Lev Gertsik

This figure shows the co-authorship network connecting the top 25 collaborators of Lev Gertsik. A scholar is included among the top collaborators of Lev Gertsik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lev Gertsik. Lev Gertsik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Umbricht, Daniel, Markus Abt, Christopher H. Chatham, et al.. (2021). Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms. SHILAP Revista de lepidopterología. 1(1). 70–77. 9 indexed citations
2.
3.
Desai, Amit, et al.. (2020). Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. Clinical Pharmacokinetics. 60(1). 79–88. 3 indexed citations
4.
Gertsik, Lev, et al.. (2019). Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 6(2). 135–138. 4 indexed citations
5.
DeMartinis, Nicholas, Eve H. Pickering, Christopher J. Schmidt, et al.. (2019). A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia. Journal of Clinical Psychopharmacology. 39(4). 318–328. 20 indexed citations
6.
Lee, Sophie, et al.. (2019). P4‐026: DEPRESSIVE SYMPTOMATOLOGY PREDICTS WILLINGNESS TO PARTICIPATE IN CLINICAL TRIALS. Alzheimer s & Dementia. 15(7S_Part_24). 1 indexed citations
7.
Umbricht, Daniel, Juergen Dukart, Markus Abt, et al.. (2018). S43. A PROOF-OF-MECHANISM STUDY OF THE PDE10 INHIBITOR RG7203 IN PATIENTS WITH PROBING REWARD FUNCTIONS WITH IMAGING AND BEHAVIORAL APPROACHES. Schizophrenia Bulletin. 44(suppl_1). S340–S341. 2 indexed citations
8.
9.
Litman, Robert E., Mark A. Smith, James Doherty, et al.. (2016). AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Schizophrenia Research. 172(1-3). 152–157. 66 indexed citations
10.
Fava, Maurizio, Karl Johe, Larry Ereshefsky, et al.. (2015). A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Molecular Psychiatry. 21(10). 1372–1380. 38 indexed citations
11.
Martin, Patrick, Bryan Dirks, Lev Gertsik, et al.. (2014). Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia. Journal of Clinical Psychopharmacology. 34(6). 682–689. 14 indexed citations
12.
English, Brett A., et al.. (2014). P4‐357: EFFECTS OF SCOPOLAMINE ON WORKING MEMORY TASK AND RESTING FUNCTIONAL CONNECTIVITY USING FMRI IN HEALTHY KOREAN SUBJECTS. Alzheimer s & Dementia. 10(4S_Part_16). 1 indexed citations
13.
Poland, Russell E., Ira M. Lesser, Yu‐Jui Yvonne Wan, et al.. (2013). Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life Sciences. 92(20-21). 967–970. 10 indexed citations
14.
English, Brett A., et al.. (2013). Use of Translational Pharmacodynamic Biomarkers in Early-Phase Clinical Studies for Schizophrenia. Biomarkers in Medicine. 8(1). 29–49. 10 indexed citations
15.
Poland, Russell E., et al.. (2012). Open-Label, Randomized, Parallel-Group Controlled Clinical Trial of Massage for Treatment of Depression in HIV-Infected Subjects. The Journal of Alternative and Complementary Medicine. 19(4). 334–340. 10 indexed citations
16.
Bursi, Roberta, Peter Dogterom, Larry Ereshefsky, et al.. (2012). Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients. Drugs in R&D. 12(3). 127–139. 17 indexed citations
17.
Gertsik, Lev, Russell E. Poland, Catherine Bresee, & Mark Hyman Rapaport. (2011). Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology. 32(1). 61–64. 129 indexed citations
18.
Ereshefsky, Larry, et al.. (2011). Strategies to accelerate drug development for CNS compounds. International Clinical Psychopharmacology. 26. e59–e59. 1 indexed citations
19.
Rao, Uma, Geoffrey E. Ott, Keh‐Ming Lin, Lev Gertsik, & Russell E. Poland. (2004). Effect of bupropion on nocturnal urinary free cortisol and its association with antidepressant response. Journal of Psychiatric Research. 39(2). 183–190. 11 indexed citations
20.
Ott, Geoffrey E., Uma Rao, Keh‐Ming Lin, Lev Gertsik, & Russell E. Poland. (2004). Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response. The International Journal of Neuropsychopharmacology. 7(3). 275–281. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nuria García‐Marchena Breakdown of academic impact, for papers by Janice Shaw Breakdown of academic impact, for papers by Haruhiko Sugino Breakdown of academic impact, for papers by Lucija Tudor Breakdown of academic impact, for papers by Marie Naughton Breakdown of academic impact, for papers by Luke A. Jelen Breakdown of academic impact, for papers by Hans‐Willi Clement Breakdown of academic impact, for papers by Ani Gasparyan Breakdown of academic impact, for papers by Martha López-Canul Breakdown of academic impact, for papers by David Nutt
Rankless by CCL
2026